Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,690JPY
18 May 2018
Change (% chg)

¥-49 (-1.03%)
Prev Close
¥4,739
Open
¥4,711
Day's High
¥4,733
Day's Low
¥4,682
Volume
5,379,500
Avg. Vol
3,981,325
52-wk High
¥6,693
52-wk Low
¥4,398

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.63
Market Cap(Mil.): ¥3,727,088.00
Shares Outstanding(Mil.): 794.69
Dividend: 90.00
Yield (%): 3.84

Financials

  4502.T Industry Sector
P/E (TTM): 19.75 28.57 32.53
EPS (TTM): 237.49 -- --
ROI: 5.94 13.08 12.63
ROE: 9.60 14.80 14.50

Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion (46 billion pound) deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

17 May 2018

Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

17 May 2018

FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal

* Takeda boss to raise bar for pipeline drugs after Shire deal

17 May 2018

Takeda sees lower annual profit, generics to erode cancer drug sales

TOKYO Japan's Takeda Pharmaceutical Co Ltd on Monday forecast a 17 percent drop in operating profit for the year through March 2019 as blood cancer drug Velcade looks set to face generic competition in the United States.

14 May 2018

UPDATE 2-Takeda sees lower annual profit, generics to erode cancer drug sales

* Takeda looking to strengthen pipeline by acquiring Shire (Adds executive comment, details)

14 May 2018

Takeda forecasts 17 percent profit decline on Velcade U.S. exclusivity loss

TOKYO Japan's Takeda Pharmaceutical Co Ltd on Monday forecast a 17 percent fall in operating profit for the year through March 2019 as blood cancer drug Velcade looks set to lose exclusivity in the U.S.

14 May 2018

Takeda posts 55 pct jump in annual profit, beats estimates

TOKYO, May 14 Japan's Takeda Pharmaceutical Co Ltd reported on Monday a 55.1 percent jump in annual operating profit, buoyed by growing sales of bowel disease drug Entyvio and heartburn and ulcer drug Takecab.

14 May 2018

Takeda smashes Asian loan record

* Loans: JP Morgan leads US$30.85bn bridge for Shire acquisition

14 May 2018

IWG receives takeover approaches from three suitors

LONDON British serviced office provider IWG has attracted takeover approaches from three rival suitors, potentially plunging the $3.1 billion company into a bidding war.

11 May 2018

Britain's IWG receives takeover approaches from three suitors

LONDON British serviced office provider IWG has attracted takeover approaches from three rival suitors, potentially plunging the $3.1 billion company into a bidding war.

11 May 2018

Earnings vs. Estimates